{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:08:35Z","timestamp":1791212915078,"version":"4.1.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2009,8,7]],"date-time":"2009-08-07T00:00:00Z","timestamp":1249603200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1007\/s12032-009-9278-9","type":"journal-article","created":{"date-parts":[[2009,8,6]],"date-time":"2009-08-06T18:45:02Z","timestamp":1249584302000},"page":"743-746","source":"Crossref","is-referenced-by-count":28,"title":["Expression of complement regulatory proteins: CD46, CD55, and CD59 and response to rituximab in patients with CD20(+) non-Hodgkin\u2019s lymphoma"],"prefix":"10.1007","volume":"27","author":[{"given":"Justyna","family":"Dzietczenia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Wr\u00f3bel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz","family":"Mazur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafa\u0142","family":"Por\u0119ba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo\u017cena","family":"Ja\u017awiec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazimierz","family":"Kuliczkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,8,7]]},"reference":[{"key":"9278_CR1","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1182\/blood.V95.12.3900","volume":"95","author":"J Golay","year":"2000","unstructured":"Golay J, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood. 2000;95:3900\u20138.","journal-title":"Blood"},{"key":"9278_CR2","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1042\/bst0250705","volume":"25","author":"DR Andersen","year":"1997","unstructured":"Andersen DR, Grillo-Lopez A, Varnas C, Chambers KS, Hanna N. Targeted anti-cancer therapy using rituximab, a chimeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin\u2019s B-cell lymphoma. Biochem Soc Trans. 1997;25:705\u20138.","journal-title":"Biochem Soc Trans"},{"key":"9278_CR3","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.imlet.2007.04.014","volume":"111","author":"P Macor","year":"2007","unstructured":"Macor P, Tedesco F. Complement as effector system in cancer immunotherapy. Immunol Lett. 2007;111:6\u201313.","journal-title":"Immunol Lett"},{"key":"9278_CR4","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.it.2004.07.004","volume":"25","author":"RC Riley-Vargas","year":"2004","unstructured":"Riley-Vargas RC, Gill DB, Kemper C, Liszewski MK, Atkinson JP. CD46: expanding beyond complement regulation. Trends Immunol. 2004;25:496\u2013503.","journal-title":"Trends Immunol"},{"key":"9278_CR5","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1002\/eji.200425920","volume":"35","author":"F Ziller","year":"2005","unstructured":"Ziller F, et al. Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59. Eur J Immunol. 2005;35:2175\u201383.","journal-title":"Eur J Immunol"},{"key":"9278_CR6","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0161-5890(99)00115-7","volume":"36","author":"K Jurianz","year":"1999","unstructured":"Jurianz K, et al. Complement resistance of tumor cells: basal and induced mechanism. Mol Immunol. 1999;36:929\u201339.","journal-title":"Mol Immunol"},{"key":"9278_CR7","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1007\/s00262-003-0402-y","volume":"52","author":"LG Durrant","year":"2003","unstructured":"Durrant LG, et al. Enhanced expression of the complement regulatory proteins predicts a poor prognosis in colorectal cancer patients. Cancer Immunol Immunother. 2003;52:638\u201342.","journal-title":"Cancer Immunol Immunother"},{"key":"9278_CR8","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/labinvest.3780038","volume":"80","author":"VT Blok","year":"2000","unstructured":"Blok VT, et al. A possible role of CD46 for the protection in vivo of human renal tumor cells from complement-mediated damage. Lab Invest. 2000;80:335\u201344.","journal-title":"Lab Invest"},{"key":"9278_CR9","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1182\/blood.V98.12.3383","volume":"98","author":"J Golay","year":"2001","unstructured":"Golay J, et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood. 2001;98:3383\u20139.","journal-title":"Blood"},{"key":"9278_CR10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1034\/j.1600-0609.2000.80097.x","volume":"64","author":"D Guc","year":"2000","unstructured":"Guc D, Canpmar H, Kucukasu C, Kansu E. Expression of complement regulatory proteins CR1, DAF, MCP and CD59 in haematological malignancies. Eur J Haematol. 2000;64:3\u20139.","journal-title":"Eur J Haematol"},{"key":"9278_CR11","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1182\/blood.V98.5.1352","volume":"98","author":"WK Weng","year":"2001","unstructured":"Weng WK, Levy R. Expression of complement inhibitors CD46, CD55 and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood. 2001;98:1352\u20137.","journal-title":"Blood"},{"key":"9278_CR12","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.leukres.2005.09.008","volume":"30","author":"K Takei","year":"2006","unstructured":"Takei K, Yamazaki T, Sawada U, Ishizuka H, Aizawa S. Analysis of changes in CD20, CD55 and CD59 expression on established rituximab-resistant B-lymphoma cell lines. Leuk Res. 2006;30:625\u201331.","journal-title":"Leuk Res"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-009-9278-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-009-9278-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-009-9278-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T07:49:47Z","timestamp":1590047387000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-009-9278-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,7]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["9278"],"URL":"https:\/\/doi.org\/10.1007\/s12032-009-9278-9","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8,7]]}}}